Recent studies have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and dopamine neurotransmission. While GCGR agonists are commonly employed for addressing type 2 https://sabrinafejc713746.designi1.com/62303266/emerging-glp-stimulators-and-dopaminergic-influence-a-comparative-overview